Sage Therapeutics Explores Alternatives, Rejects Biogen's Proposal, Stock Up
(RTTNews) - Sage Therapeutics, Inc. (SAGE) Monday announced that its Board of Directors has initiated a strategic review process aimed at maximizing shareholder value, involving a wide range of ...
Sage rejects Biogen's $469 million takeover offer, says offer undervalues company
Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it ...
Sage rejects Biogen's $469 million takeover offer
Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen. The ...
Sage Rejects Biogen’s Takeover Offer, Will Explore Options
Sage Therapeutics Inc. rejected a takeover offer from drugmaker Biogen Inc. and said it has started exploring possible options including a sale.
Sage Rejects Biogen Bid, Launches Review of Alternatives
Sage Therapeutics has rejected a buyout bid from partner Biogen and launched a review of strategic alternatives. Sage on Monday said its board determined that Biogen's $7.22-a-share proposal ...
Sage rejects Biogen’s buyout offer, but says it's open to deals
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...
STAT1h
U.S. health agencies see some chaos — but an FDA approval gets through
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Sage rejects Biogen's takeover offer, to explore strategic alternatives
Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen and added ...
Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal
Sage Therapeutics, Inc. (Nasdaq: SAGE) ("Sage" or "the Company"), today announced that its Board of Directors has initiated a process to explore strategic alternatives for the Company. The Board ...
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...
Sage Therapeutics rejects Biogen bid, starts strategic review
Sage Therapeutics rejected a takeover offer from Biogen ( BIIB) and said it started a process to review its strategic ...
Sage Therapeutics shares rise amid strategic review
Investing.com -- Sage Therapeutics, Inc. (NASDAQ: SAGE) stock climbed 2.5% today, reflecting investor sentiment after the company announced the initiation of a strategic review process and the ...